PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.578
https://www.valueinhealthjournal.com/article/S1098-3015(19)32956-0/fulltext
Title :
PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32956-0&doi=10.1016/j.jval.2019.09.578
First page :
Section Title :
Open access? :
No
Section Order :
10496